Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Non-Current ReceivablesReceivables - NetReceivables - OtherReceivables Refunds
Ratios

Sanofi (SNY) Non-Current Receivables (2018 - 2025)

Sanofi's Non-Current Receivables history spans 8 years, with the latest figure at $640.2 million for Q4 2025.

  • For Q4 2025, Non-Current Receivables rose 6.99% year-over-year to $640.2 million; the TTM value through Dec 2025 reached $640.2 million, up 6.99%, while the annual FY2025 figure was $621.4 million, 2.52% up from the prior year.
  • Non-Current Receivables for Q4 2025 was $640.2 million at Sanofi, up from $598.4 million in the prior quarter.
  • Across five years, Non-Current Receivables topped out at $640.2 million in Q4 2025 and bottomed at $200.2 million in Q4 2021.
  • The 5-year median for Non-Current Receivables is $246.9 million (2022), against an average of $377.6 million.
  • The largest annual shift saw Non-Current Receivables crashed 32.3% in 2021 before it surged 195.84% in 2024.
  • A 5-year view of Non-Current Receivables shows it stood at $200.2 million in 2021, then rose by 23.33% to $246.9 million in 2022, then dropped by 18.07% to $202.3 million in 2023, then skyrocketed by 195.84% to $598.4 million in 2024, then rose by 6.99% to $640.2 million in 2025.
  • Per Business Quant, the three most recent readings for SNY's Non-Current Receivables are $640.2 million (Q4 2025), $598.4 million (Q4 2024), and $202.3 million (Q4 2023).